Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-12-18 00:00:00 ET · period of report 2025-12-16 · accession 0002001011-25-000127 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-18 | 2025-12-16 | LGND | Espinoza Octavio | CFO | M - OptEx | $69.00 | +2,381 | 27.4K | +9% | +$164.3K |
| DM | 2025-12-18 | 2025-12-16 | LGND | Espinoza Octavio | CFO | M - OptEx | $0.00 | -2,381 | 972 | -71% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-16 | M | A | 1,194 | $52.84 | 27,380 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-16 | M | A | 181 | $103.42 | 28,567 | D | — | — | |
| 3 | Common | Common Stock | 2025-12-16 | M | A | 652 | $92.65 | 28,386 | D | — | — | |
| 4 | Common | Common Stock | 2025-12-16 | M | A | 285 | $63.62 | 27,734 | D | — | — | |
| 5 | Common | Common Stock | 2025-12-16 | M | A | 69 | $57.22 | 27,449 | D | — | — | |
| 6 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 285 | $0.00 | 18,171 | D | $63.62 · — to 2032-12-13 | 285 Common Stock | (F3) Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 181 | $0.00 | 4,186 | D | $103.42 · — to 2031-02-03 | 181 Common Stock | (F5) The stock option vests as to 50% of the underlying shares on January 3, 2025 and as to the remaining on February 3, 2025. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 652 | $0.00 | 2,405 | D | $92.65 · — to 2028-03-02 | 652 Common Stock | (F4) The stock option is fully vested and exercisable. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 69 | $0.00 | 7,171 | D | $57.22 · — to 2030-10-01 | 69 Common Stock | (F2) As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. |
| 10 | Derivative | Employee Stock Option (right to buy) | 2025-12-16 | M | D | 1,194 | $0.00 | 972 | D | $52.84 · — to 2032-05-05 | 1,194 Common Stock | (F1) The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter. |